Abstract:a b s t r a c tObjective: To evaluate if transcranial magnetic stimulation (TMS) measures correlate with disease severity and predict functional decline in frontotemporal dementia (FTD) phenotypes. Methods: Paired-pulse TMS was used to investigate the activity of different intracortical circuits in 171 FTD patients (122 bvFTD, 31 avPPA, 18 svPPA) and 74 healthy controls. Pearson's correlations were used to analyze the association between TMS measures and disease severity, while multiple regression analysis was… Show more
“…We also observed an association between serum GFAP concentration and indirect measures of GABAergic neurotransmission, which have been demonstrated to be impaired in FTLD (Benussi et al, 2019aPadovani et al, 2018), and reflect disease severity and progression (Benussi et al, 2020b(Benussi et al, , 2020a. We observed that the higher the serum GFAP concentration, the greater was the impairment in LICI, which is considered to reflect short-lasting postsynaptic inhibition mediated through the GABAB receptors at the level of local interneurons (Rossini et al, 2015;Ziemann et al, 2015).…”
Background: It is still unknown if serum glial fibrillary acidic protein (GFAP) is a useful marker in frontotemporal lobar degeneration (FTLD). Objective: To assess the diagnostic and prognostic value of serum GFAP in a large cohort of patients with FTLD. Methods: In this retrospective study, performed on 406 participants, we measured serum GFAP concentration with an ultrasensitive Single molecule array (Simoa) method in patients with FTLD, Alzheimer’s disease (AD), and in cognitively unimpaired elderly controls. We assessed the role of GFAP as marker of disease severity by analyzing the correlation with clinical variables, neurophysiological data, and cross-sectional brain imaging. Moreover, we evaluated the role of serum GFAP as a prognostic marker of disease survival. Results: We observed significantly higher levels of serum GFAP in patients with FTLD syndromes, except progressive supranuclear palsy, compared with healthy controls, but not compared with AD patients. In FTLD, serum GFAP levels correlated with measures of cognitive dysfunction and disease severity, and were associated with indirect measures of GABAergic deficit. Serum GFAP concentration was not a significant predictor of survival. Conclusion: Serum GFAP is increased in FTLD, correlates with cognition and GABAergic deficits, and thus shows promise as a biomarker of disease severity in FTLD.
“…We also observed an association between serum GFAP concentration and indirect measures of GABAergic neurotransmission, which have been demonstrated to be impaired in FTLD (Benussi et al, 2019aPadovani et al, 2018), and reflect disease severity and progression (Benussi et al, 2020b(Benussi et al, , 2020a. We observed that the higher the serum GFAP concentration, the greater was the impairment in LICI, which is considered to reflect short-lasting postsynaptic inhibition mediated through the GABAB receptors at the level of local interneurons (Rossini et al, 2015;Ziemann et al, 2015).…”
Background: It is still unknown if serum glial fibrillary acidic protein (GFAP) is a useful marker in frontotemporal lobar degeneration (FTLD). Objective: To assess the diagnostic and prognostic value of serum GFAP in a large cohort of patients with FTLD. Methods: In this retrospective study, performed on 406 participants, we measured serum GFAP concentration with an ultrasensitive Single molecule array (Simoa) method in patients with FTLD, Alzheimer’s disease (AD), and in cognitively unimpaired elderly controls. We assessed the role of GFAP as marker of disease severity by analyzing the correlation with clinical variables, neurophysiological data, and cross-sectional brain imaging. Moreover, we evaluated the role of serum GFAP as a prognostic marker of disease survival. Results: We observed significantly higher levels of serum GFAP in patients with FTLD syndromes, except progressive supranuclear palsy, compared with healthy controls, but not compared with AD patients. In FTLD, serum GFAP levels correlated with measures of cognitive dysfunction and disease severity, and were associated with indirect measures of GABAergic deficit. Serum GFAP concentration was not a significant predictor of survival. Conclusion: Serum GFAP is increased in FTLD, correlates with cognition and GABAergic deficits, and thus shows promise as a biomarker of disease severity in FTLD.
“…Cortex hyperexcitability as highlighted by a lower RMT, in fact, is a key feature of both ALS and FTD [ 116 ]. Same findings were replicated in a larger cohort of FTD patients using the Mini Mental State Examination test [ 117 ].…”
Background and aim
Amyotrophic lateral sclerosis (ALS) is a progressive neurodegenerative disorder characterized by the degeneration of both upper and lower motoneurons in the brain and spinal cord leading to motor and extra-motor symptoms. Although traditionally considered a pure motor disease, recent evidences suggest that ALS is a multisystem disorder. Neuropsychological alterations, in fact, are observed in more than 50% of patients: while executive dysfunctions have been firstly identified, alterations in verbal fluency, behavior, and pragmatic and social cognition have also been described. Detecting and monitoring ALS cognitive and behavioral impairment even at early disease stages is likely to have staging and prognostic implications, and it may impact the enrollment in future clinical trials. During the last 10 years, humoral, radiological, neurophysiological, and genetic biomarkers have been reported in ALS, and some of them seem to potentially correlate to cognitive and behavioral impairment of patients. In this review, we sought to give an up-to-date state of the art of neuropsychological alterations in ALS: we will describe tests used to detect cognitive and behavioral impairment, and we will focus on promising non-invasive biomarkers to detect pre-clinical cognitive decline.
Conclusions
To date, the research on humoral, radiological, neurophysiological, and genetic correlates of neuropsychological alterations is at the early stage, and no conclusive longitudinal data have been published. Further and longitudinal studies on easily accessible and quantifiable biomarkers are needed to clarify the time course and the evolution of cognitive and behavioral impairments of ALS patients.
“…SAI is not different in patients with FTD compared to healthy subjects; this is to be expected given that SAI reflects cholinergic transmission, which is not typically involved in FTD. As well as being correlated with the FTLD-CDR (a clinical rating scale to measure FTD severity), it was found that less SICI is associated with greater clinical progression of FTD (120). The interpretation was that, rather than reflecting impairments of a specific interneuron circuit, these abnormalities reflect an inability to integrate two, closely timed pulses.…”
Section: Tms Measures Correlate With Cognitive Symptoms and Predicts Functional Declinementioning
confidence: 98%
“…Early studies of CSE in patients with FTD showed no changes compared to healthy subjects (103,118). However, a series of studies by Benussi et al have investigated intracortical circuits in a large number of FTD patients, finding that both intracortical facilitation (ICF and SICF) and inhibition (SICI and LICI) are lower in FTD than in healthy controls (119)(120)(121).…”
Section: Corticospinal Excitability In Dementiasmentioning
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.